Published in Curr Med Chem on April 12, 2017
Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: a large population-based study. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
Statin use and reduced cancer-related mortality. N Engl J Med (2012) 8.51
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
Immortal time bias in pharmaco-epidemiology. Am J Epidemiol (2007) 6.98
Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol (2013) 5.28
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol (2014) 3.72
Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res (1991) 3.24
Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther (2009) 3.15
Drug discovery. Repurposing with a difference. Science (2009) 2.97
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 2.89
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology (2002) 2.84
Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol (2004) 2.70
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol (2015) 2.05
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS One (2015) 1.76
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res (2010) 1.76
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol (2014) 1.64
Global guideline for type 2 diabetes. Diabetes Res Clin Pract (2014) 1.41
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One (2013) 1.29
Metformin in cancer treatment and prevention. Annu Rev Med (2014) 1.23
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun (2012) 1.19
Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res (2010) 1.18
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol (2013) 1.16
Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas (2013) 1.12
Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. PLoS One (2013) 1.12
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis (2013) 1.08
The potential of statins as part of anti-cancer treatment. Eur J Cancer (2005) 1.07
Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas (2013) 1.03
Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS One (2014) 1.03
Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am J Gastroenterol (2015) 0.99
The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Cancer Res Treat (2015) 0.98
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem (2014) 0.98
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clin Cancer Res (2015) 0.95
Statin use and all-cancer survival: prospective results from the Women's Health Initiative. Br J Cancer (2016) 0.95
Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. Pancreas (2015) 0.91
Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Pancreas (2016) 0.91
Drug repurposing and the medicinal chemist. ACS Med Chem Lett (2012) 0.86
Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. Anticancer Res (2014) 0.84
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Dig Liver Dis (2015) 0.83
Potential anticancer effects of statins: fact or fiction? Endothelium (2003) 0.81
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS One (2016) 0.81
Metformin may improve the prognosis of patients with pancreatic cancer. Asian Pac J Cancer Prev (2015) 0.80
Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. J Gastrointest Surg (2011) 0.80
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Medicine (Baltimore) (2016) 0.78
Safety issues on metformin use. Diabetes Care (2003) 0.78
Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late? Clin Cancer Res (2015) 0.77